标题
Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives
作者
关键词
-
出版物
Cancers
Volume 13, Issue 22, Pages 5660
出版商
MDPI AG
发表日期
2021-11-12
DOI
10.3390/cancers13225660
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- The diagnostic and clinicopathological value of trefoil factor 3 in patients with gastric cancer: a systematic review and meta-analysis
- (2021) Chen-Xing Zhang et al. BIOMARKERS
- A systematic review of microRNAs as potential biomarkers for diagnosis and prognosis of gastric cancer
- (2021) Alireza Ahadi IMMUNOGENETICS
- FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18.2 positive gastric and gastro-oesophageal adenocarcinoma
- (2021) U. Sahin et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)
- (2021) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
- (2021) Ronan J. Kelly et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Landscape of Gastric Carcinoma Tumor Microenvironment Identifies a Peritoneal Relapse Relevant Immune Signature
- (2021) Chuang Zhang et al. Frontiers in Immunology
- An overview of precision oncology basket and umbrella trials for clinicians
- (2020) Jay J. H. Park et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study
- (2020) E. Van Cutsem et al. EUROPEAN JOURNAL OF CANCER
- High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features
- (2020) Xiaoqiao Liu et al. PATHOLOGY RESEARCH AND PRACTICE
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy
- (2020) Ziyu Li et al. Science Advances
- Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study
- (2020) Akihito Kawazoe et al. EUROPEAN JOURNAL OF CANCER
- Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study)
- (2020) Akitaka Makiyama et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
- (2020) Yelena Y Janjigian et al. LANCET ONCOLOGY
- Noncoding RNAs in gastric cancer: implications for drug resistance
- (2020) Ling Wei et al. Molecular Cancer
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit
- (2020) Bailiang Li et al. JCI Insight
- A rapid and highly sensitive biomarker detection platform based on a temperature-responsive liposome-linked immunosorbent assay
- (2020) Runkai Hu et al. Scientific Reports
- Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment
- (2020) Xiao-Jing Shi et al. Frontiers in Molecular Biosciences
- The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer
- (2020) María Alarcón et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
- (2020) Markus Moehler et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
- (2020) Hyun Cheol Chung et al. Future Oncology
- Epigenomic promoter alterations predict for benefit from immune checkpoint inhibition in metastatic gastric cancer
- (2019) R Sundar et al. ANNALS OF ONCOLOGY
- Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures
- (2019) Dongqiang Zeng et al. Cancer Immunology Research
- Peripheral Venous Blood Platelet-to-Lymphocyte Ratio (PLR) for Predicting the Survival of Patients With Gastric Cancer Treated With SOX or XELOX Regimen Neoadjuvant Chemotherapy
- (2019) Li Chen et al. TECHNOLOGY IN CANCER RESEARCH & TREATMENT
- Clinical Application of Circulating Tumor Cells in Gastric Cancer
- (2019) Moon Won Lee et al. Gut and Liver
- Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
- (2019) Manish A. Shah et al. Gastric Cancer
- The predictive value of the preoperative C-reactive protein–albumin ratio for early recurrence and chemotherapy benefit in patients with gastric cancer after radical gastrectomy: using randomized phase III trial data
- (2019) Bin-bin Xu et al. Gastric Cancer
- Trastuzumab With S-1 Plus Cisplatin in HER2-positive Advanced Gastric Cancer Without Measurable Lesions: OGSG 1202
- (2019) SHUNJI ENDO et al. ANTICANCER RESEARCH
- Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial
- (2019) Fernando Rivera et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer
- (2019) Elizabeth Won et al. CLINICAL CANCER RESEARCH
- A phase I/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer
- (2019) Tae-Yong Kim et al. Gastric Cancer
- Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer
- (2019) Daisuke Takahari et al. Gastric Cancer
- The role of visfatin in cancer proliferation, angiogenesis, metastasis, drug resistance and clinical prognosis
- (2019) Tsung-Chieh Lin Cancer Management and Research
- Prediction of Chronic Atrophic Gastritis and Gastric Neoplasms by Serum Pepsinogen Assay: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy
- (2019) Bang et al. Journal of Clinical Medicine
- Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
- (2019) F Wang et al. ANNALS OF ONCOLOGY
- Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance
- (2019) Simon Pernot et al. Gastric Cancer
- Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
- (2019) Tianshu Liu et al. Cancer Communications
- Pralatrexate in combination with oxaliplatin in advanced esophago-gastric cancer: a phase II trial with predictive molecular correlates
- (2019) Usha Malhotra et al. MOLECULAR CANCER THERAPEUTICS
- Role of miR‑34 in gastric cancer: From bench to bedside (Review)
- (2019) Shengwei Xiong et al. ONCOLOGY REPORTS
- 198TiPSPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
- (2019) K Yamaguchi et al. ANNALS OF ONCOLOGY
- Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2‐positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study
- (2019) Kohei Shitara et al. Asia-Pacific Journal of Clinical Oncology
- Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B
- (2019) Satoshi Yuki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
- (2019) Ronan J. Kelly et al. CLINICAL CANCER RESEARCH
- Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
- (2018) S T Kim et al. ANNALS OF ONCOLOGY
- Microsatellite Instability and Programmed Cell Death-Ligand 1 Expression in Stage II/III Gastric Cancer
- (2018) Yoon Young Choi et al. ANNALS OF SURGERY
- Detection of carcinoembryonic antigen in peritoneal fluid of patients undergoing laparoscopic distal gastrectomy with complete mesogastric excision
- (2018) D. Xie et al. BRITISH JOURNAL OF SURGERY
- Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial
- (2018) Kakoli Das et al. CANCER LETTERS
- Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
- (2018) Manish A. Shah et al. CLINICAL CANCER RESEARCH
- Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801)
- (2018) Michael Stahl et al. EUROPEAN JOURNAL OF CANCER
- The Reprimo Gene Family: A Novel Gene Lineage in Gastric Cancer with Tumor Suppressive Properties
- (2018) Julio Amigo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis
- (2018) Jae-Ho Cheong et al. LANCET ONCOLOGY
- Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer
- (2018) Giandomenico Roviello et al. MEDICINE
- Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis
- (2018) Yanjie You et al. Molecular Medicine Reports
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- (2018) Seung Tae Kim et al. NATURE MEDICINE
- Epigenetic Mechanisms and Events in Gastric Cancer-Emerging Novel Biomarkers
- (2018) Puneet et al. PATHOLOGY & ONCOLOGY RESEARCH
- Positive cytoplasmic UCHL5 tumor expression in gastric cancer is linked to improved prognosis
- (2018) Leena Arpalahti et al. PLoS One
- Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial
- (2018) Michael Nagel et al. TUMOR BIOLOGY
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer
- (2018) Yosuke Horita et al. ANTI-CANCER DRUGS
- Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)
- (2018) Markus Moehler et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches
- (2018) Margherita Ratti et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer
- (2018) Sebastian Mondaca et al. Gastric Cancer
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD‐L1
- (2018) Lola Fashoyin‐Aje et al. ONCOLOGIST
- Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in China
- (2018) Jing Huang et al. CANCER
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer
- (2018) Funda Meric-Bernstam et al. CLINICAL CANCER RESEARCH
- The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies
- (2018) Christine Garcia et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial
- (2018) Jun Lu et al. Gastric Cancer
- EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer
- (2018) Francisco Sanchez-Vega et al. Cancer Discovery
- Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
- (2018) Yasuko Tada et al. Journal for ImmunoTherapy of Cancer
- A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer
- (2018) Y.-J. Bang et al. EUROPEAN JOURNAL OF CANCER
- Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
- (2017) Simon Pernot et al. EUROPEAN JOURNAL OF CANCER
- Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G)
- (2017) Yuji Miura et al. Gastric Cancer
- Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06)
- (2017) Yutaka Kimura et al. Gastric Cancer
- HER2 testing in gastric cancer: results of a German expert meeting
- (2017) Florian Lordick et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- (2017) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- C-C motif chemokine 22 ligand (CCL22) concentrations in sera of gastric cancer patients are related to peritoneal metastasis and predict recurrence within one year after radical gastrectomy
- (2017) Yuzhe Wei et al. JOURNAL OF SURGICAL RESEARCH
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes
- (2017) Shinji Kitamura et al. ONCOLOGY
- Circular RNA hsa_circ_0000745 may serve as a diagnostic marker for gastric cancer
- (2017) Mei Huang et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The role of miRNA and lncRNA in gastric cancer
- (2017) Ning-Bo Hao et al. Oncotarget
- Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer
- (2017) Hyo Song Kim et al. Oncotarget
- Early detection of gastric cancer using global, genome-wide and IRF4, ELMO1, CLIP4 and MSC DNA methylation in endoscopic biopsies
- (2017) Francesca Pirini et al. Oncotarget
- Evaluation of Intratumoral and Intertumoral Heterogeneity of MET Protein Expression in Gastric Cancer
- (2017) Jiwoon Choi et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Correlation of Caveolin-1 Expression with Prognosis in Patients with Gastric Cancer after Gastrectomy
- (2017) Mesut Seker et al. Oncology Research and Treatment
- Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma
- (2017) Manish A. Shah et al. JAMA Oncology
- Mismatch Repair Deficiency, Microsatellite Instability, and Survival
- (2017) Elizabeth C. Smyth et al. JAMA Oncology
- Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
- (2016) Markus Moehler et al. BMC CANCER
- Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
- (2016) Jifang Gong et al. BMC CANCER
- Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis
- (2016) Changhoon Yoo et al. BRITISH JOURNAL OF CANCER
- Evaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial
- (2016) Ulrich T Hacker et al. BRITISH JOURNAL OF CANCER
- Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study
- (2016) Didier Meulendijks et al. CANCER
- A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer
- (2016) Hiromi Kataoka et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002)
- (2016) A. Tsuburaya et al. CLINICAL ONCOLOGY
- Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)
- (2016) Seung Tae Kim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Gastric cancer
- (2016) Eric Van Cutsem et al. LANCET
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment
- (2016) Jaehong Kim et al. MEDIATORS OF INFLAMMATION
- A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer
- (2016) M. J. LaBonte et al. MOLECULAR CANCER THERAPEUTICS
- HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
- (2016) Michael F. Press et al. MOLECULAR CANCER THERAPEUTICS
- Overexpression and Biological Function of Ubiquitin-Specific Protease 42 in Gastric Cancer
- (2016) Kun Hou et al. PLoS One
- Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer
- (2016) Xiaobin Gu et al. Oncotarget
- HER2 Status in Gastric and Gastroesophageal Junction Cancer
- (2016) Woo-Ho Kim et al. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
- Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma
- (2016) Hao Liu et al. Scientific Reports
- Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
- (2015) M Zhu et al. BRITISH JOURNAL OF CANCER
- Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers
- (2015) Zev A. Wainberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2015) Sylvie Lorenzen et al. EUROPEAN JOURNAL OF CANCER
- Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer
- (2015) Min-Hee Ryu et al. EUROPEAN JOURNAL OF CANCER
- Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer
- (2015) Maria Di Bartolomeo et al. Gastric Cancer
- BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer
- (2015) Tomohiro Kubo et al. Gastric Cancer
- Phase II trial of dacomitinib in patients with HER2-positive gastric cancer
- (2015) Do-Youn Oh et al. Gastric Cancer
- Pri-miR-34b/c rs4938723 Polymorphism Is Associated with a Decreased Risk of Gastric Cancer
- (2015) Xin-Min Pan et al. Genetic Testing and Molecular Biomarkers
- Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study
- (2015) Didier Meulendijks et al. INVESTIGATIONAL NEW DRUGS
- Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer
- (2015) Yung-Jue Bang et al. JOURNAL OF CLINICAL ONCOLOGY
- Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer
- (2015) Long-Jun He WORLD JOURNAL OF GASTROENTEROLOGY
- The association analysis of lncRNA HOTAIR genetic variants and gastric cancer risk in a Chinese population
- (2015) Mulong Du et al. Oncotarget
- Immunoregulatory Function of HLA-G in Gastric Cancer
- (2014) Tolga Tuncel et al. Asian Pacific Journal of Cancer Prevention
- High Monocarboxylate Transporter 4 Protein Expression in Stromal Cells Predicts Adverse Survival in Gastric Cancer
- (2014) Ping Yan et al. Asian Pacific Journal of Cancer Prevention
- Aberrant Expression of the Autocrine Motility Factor Receptor Correlates with Poor Prognosis and Promotes Metastasis in Gastric Carcinoma
- (2014) Zhen Huang et al. Asian Pacific Journal of Cancer Prevention
- Association of miR-193b Down-regulation and miR-196a up-Regulation with Clinicopathological Features and Prognosis in Gastric Cancer
- (2014) Yong-Ping Mu et al. Asian Pacific Journal of Cancer Prevention
- VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2014) Thomas Thomaidis et al. BMC CANCER
- Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer
- (2014) Mitsuru Sasako et al. Gastric Cancer
- HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial)
- (2014) Tomohiro Matsumoto et al. Gastric Cancer
- Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer
- (2014) Taroh Satoh et al. Gastric Cancer
- HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
- (2014) Eric Van Cutsem et al. Gastric Cancer
- Effect of the −2081G/A Polymorphism of the TLR4 Gene and Its Interaction with Helicobacter pylori Infection on the Risk of Gastric Cancer in Chinese Individuals
- (2014) Ping Li et al. Genetic Testing and Molecular Biomarkers
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study
- (2014) Timothy Iveson et al. LANCET ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial
- (2014) Xiaotian Zhang et al. MEDICAL ONCOLOGY
- Comprehensive molecular characterization of gastric adenocarcinoma
- (2014) Adam J. Bass et al. NATURE
- Prognostic significance of plasma chemerin levels in patients with gastric cancer
- (2014) Jian Zhang et al. PEPTIDES
- Elevated plasma visfatin levels correlate with poor prognosis of gastric cancer patients
- (2014) Guo-Wen Lu et al. PEPTIDES
- Stem Cell-Like Circulating Tumor Cells Indicate Poor Prognosis in Gastric Cancer
- (2014) Man Li et al. Biomed Research International
- Relationship between Serum Soluble Vascular Adhesion Protein-1 Level and Gastric Cancer Prognosis
- (2014) Muhammet A. Kaplan et al. Oncology Research and Treatment
- Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912
- (2013) Y. Yamada et al. ANNALS OF ONCOLOGY
- A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker
- (2013) Masahiro Hirakawa et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer
- (2013) Jin Won Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophagogastric Cancers
- (2013) Francesco Sclafani et al. Clinical Colorectal Cancer
- Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
- (2013) A.F.C. Okines et al. EUROPEAN JOURNAL OF CANCER
- Prognostic information derived from RT-PCR analysis of peritoneal fluid in gastric cancer patients: Results from a prospective multicenter clinical trial
- (2013) Shigeyuki Tamura et al. JOURNAL OF SURGICAL ONCOLOGY
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling
- (2013) Hai-bo Qiu et al. PLoS One
- Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer
- (2013) Manish A. Shah et al. PLoS One
- miR-26a Suppresses Tumor Growth and Metastasis by Targeting FGF9 in Gastric Cancer
- (2013) Min Deng et al. PLoS One
- Enhanced Expression of Long Non-Coding RNA HOTAIR Is Associated with the Development of Gastric Cancer
- (2013) Hiroyuki Endo et al. PLoS One
- The clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids in gastric cancer with clinical serosal invasion: A prospective, multicenter study
- (2013) Yoshiyuki Fujiwara et al. SURGERY
- Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial
- (2012) A. F. C. Okines et al. ANNALS OF ONCOLOGY
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
- (2012) D H Yoon et al. BRITISH JOURNAL OF CANCER
- Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer
- (2012) Liangrong Shi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment
- (2012) Kohei Shitara et al. Gastric Cancer
- LINE-1 hypomethylation in gastric cancer, detected by bisulfite pyrosequencing, is associated with poor prognosis
- (2012) Hironobu Shigaki et al. Gastric Cancer
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
- (2012) Yung-Jue Bang et al. LANCET
- Association of themiR-146aC>G,miR-149T>C,miR-196a2T>C, andmiR-499A>G polymorphisms with gastric cancer risk and survival in the korean population
- (2012) Dae Ho Ahn et al. MOLECULAR CARCINOGENESIS
- Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study
- (2012) Kentaro Shikata et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer
- (2011) S. Iqbal et al. ANNALS OF ONCOLOGY
- Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Birgit Luber et al. BMC CANCER
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study
- (2011) Akira Sawaki et al. Gastric Cancer
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk
- (2010) L. E. Wroblewski et al. CLINICAL MICROBIOLOGY REVIEWS
- High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer
- (2010) Hideaki Shimada et al. Gastric Cancer
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Cancer Biomarkers: Are We Ready for the Prime Time?
- (2010) Alok Mishra et al. Cancers
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development
- (2008) U. Sahin et al. CLINICAL CANCER RESEARCH
- Direct multiplexed measurement of gene expression with color-coded probe pairs
- (2008) Gary K Geiss et al. NATURE BIOTECHNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started